The Froedtert & MCW Cancer Network announces novel cell therapy treatment for advanced melanoma
Source: Froedtert & Medical College of Wisconsin, June 2024
Milwaukee — Today, the Froedtert & MCW Cancer Network announced it will begin to offer new treatment to patients with advanced melanoma. Lifileucel, created by Iovance, is the first cell therapy treatment to be FDA approved for the deadliest form of skin cancer.
The Clinical Cancer Center at Froedtert Hospital campus is the first center in Wisconsin with the experience and certification to offer lifileucel treatment for advanced melanoma. Physicians at the Clinical Cancer Center participated in the clinical trial that eventually led to FDA approval of lifileucel in February 2024. Amy Harker-Murray, MD, medical oncologist with the Cancer Network and MCW assistant professor, was the local principal investigator leading the trial.
“This is the first targeted, personalized therapy we’re able offer our patients who don’t respond to other treatments for advanced melanoma,” Dr. Harker-Murray said. “As an academic medical center, we have the expertise in pathology, surgical and medical oncology, cell therapy lab, pharmacy and inpatient/outpatient teams to coordinate the complex care required to treat these patients.”